Nektar Therapeutics Release: Exubera Hailed As Innovation In Prestigious European And American Awards
SAN CARLOS, Calif.--(BUSINESS WIRE)--Sept. 12, 2006--Nektar Therapeutics (Nasdaq:NKTR):
-- WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people world-wide. It is a real breakthrough."